Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice

Bone

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Joki, Nobuhiko ^a   Nikolov, Igor G ^a,b   Caudrillier, Axelle ^b   Mentaverri, Romuald ^b   Massy, Ziad A ^b   Drüeke, Tilman B ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Atherosclerosis; Calcimimetics; Calcium sensing receptor; CKD; Vascular calcification

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; CINACALCET; R 568; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; DENSITOMETRY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERPARATHYROIDISM; MINERALIZATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UREMIA; VASCULAR LESION;

ANIMALS; ATHEROSCLEROSIS; CALCINOSIS; CALCIUM; MICE; MOLECULAR MIMICRY; RECEPTORS, CALCIUM-SENSING; UREMIA; VASCULAR DISEASES;

EID: 67349185611     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.03.653     Document Type: Article

References (32)

1. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41 (2003) 11-17
2. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32 (1998) S112-S119
3. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18 (2003) 1731-1740
4. Kennedy R., Case C., Fathi R., Johnson D., Isbel N., and Marwick T.H. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?. Am. J. Med. 110 (2001) 198-204
5. Massy Z.A., Maziere C., Kamel S., Brazier M., Choukroun G., Tribouilloy C., et al. Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr. Nephrol. 20 (2005) 380-382
6. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. (2006)
7. Neves K.R., Graciolli F.G., dos Reis L.M., Graciolli R.G., Neves C.L., Magalhaes A.O., et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 71 (2007) 1262-1270
8. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68 (2005) 1793-1800
9. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350 (2004) 1516-1525
10. Brown E.M., Gamba G., Riccardi D., Lombardi M., Butters R., Kifor O., et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366 (1993) 575-580
11. Ziegelstein R.C., Xiong Y., He C., and Hu Q. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem. Biophys. Res. Commun. 342 (2006) 153-163
12. Smajilovic S., Hansen J.L., Christoffersen T.E., Lewin E., Sheikh S.P., Terwilliger E.F., et al. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 348 (2006) 1215-1223
13. Weston A.H., Absi M., Ward D.T., Ohanian J., Dodd R.H., Dauban P., et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and calhex 231. Circ. Res. 97 (2005) 391-398
14. Kifor O., Moore Jr. F.D., Wang P., Goldstein M., Vassilev P., Kifor I., et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81 (1996) 1598-1606
15. Gogusev J., Duchambon P., Hory B., Giovannini M., Goureau Y., Sarfati E., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51 (1997) 328-336
16. Yano S., Sugimoto T., Tsukamoto T., Chihara K., Kobayashi A., Kitazawa S., et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 58 (2000) 1980-1986
17. Molostvov G., James S., Fletcher S., Bennett J., Lehnert H., Bland R., et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am. J. Physiol. Renal. Physiol. 293 (2007) F946-F955
18. Alam M.U., Kirton J.P., Wilkinson F.L., Towers E., Sinha S., Rouhi M., et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc. Res. 81 (2009) 237-239
19. Marz W., Seelhorst U., Wellnitz B., Tiran B., Obermayer-Pietsch B., Renner W., et al. Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J. Clin. Endocrinol. Metab. 92 (2007) 2363-2369
20. Lindberg J.S., Moe S.M., Goodman W.G., Coburn J.W., Sprague S.M., Liu W., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 63 (2003) 248-254
21. Ogata H., Ritz E., Odoni G., Amann K., and Orth S.R. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. 14 (2003) 959-967
22. Lopez I., Aguilera-Tejero E., Mendoza F.J., Almaden Y., Perez J., Martin D., et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. 17 (2006) 795-804
23. Lopez I., Mendoza F.J., Aguilera-Tejero E., Perez J., Guerrero F., Martin D., et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 73 (2008) 300-307
24. Massy Z.A., Ivanovski O., Nguyen-Khoa T., Angulo J., Szumilak D., Mothu N., et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein e knockout mice. J. Am. Soc. Nephrol. 16 (2005) 109-116
25. -/-) mice with chronic renal failure. Nephrol. Dial. Transplant. 23 (2008) 82-90
26. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel M, Lacour B, Drüeke TB, Z.A M: The calcimimetic r-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein e deficient mice. Atherosclerosis in press.
27. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., Schurgers L.J., Proudfoot D., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 15 (2004) 2857-2867
28. Rashid G., Bernheim J., Green J., and Benchetrit S. Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol. Dial. Transplant. 22 (2007) 2831-2837
29. Farzaneh-Far A., Proudfoot D., Weissberg P.L., and Shanahan C.M. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem. Biophys. Res. Commun. 277 (2000) 736-740
30. Smajilovic S., Sheykhzade M., Holmegard H.N., Haunso S., and Tfelt-Hansen J. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul. Pharmacol. 47 (2007) 222-228
31. Odenwald T., Nakagawa K., Hadtstein C., Roesch F., Gohlke P., Ritz E., et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J. Am. Soc. Nephrol. 17 (2006) 655-662
32. Rybczynska A., Boblewski K., Lehmann A., Orlewska C., Foks H., Drewnowska K., et al. Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am. J. Hypertens. 18 (2005) 364-371